Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …

Treatment is complex for patients with head and neck (H&N) cancers with specific site of
disease, stage, and pathologic findings guiding treatment decision-making. Treatment …

Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

Purpose There are no approved treatments for recurrent/metastatic head and neck
squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II …

Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and
neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few …

This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

Over 90% of head and neck cancers overexpress the epidermal growth factor receptor
(EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer …

Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common cancers
worldwide. More than half of patients with HNSCC eventually experience disease …

The major development of the past decade in the first-line treatment of recurrent and/or
metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the …